Publications of the project IMMUTRAIN
Early Stage Researcher as co-author are marked in blue and project leader in black
Original papers
2019
14. Metzger P, Kirchleitner S, Kluge M, Koenig L, Hoerth Ch, Rambuscheck CA, Boehmer D, Ahlfeld J,
Kobold S, Friedel C, Endres S, Schnurr M, Duewell P.
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in
pancreatic cancer.
Journal for Immunotherapy of Cancer 2019; 7:288
JIF 8.7
13. Ruzicka M, König L, Formisano S, Boehmer D, Vick B, Heuer EM, Meinl H, Kocheise L,
Zeitlhoefler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I,
Lichtenegger F, Rothenfusser S.
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to
checkpoint blockade.
Leukemia 2019
JIF 9.9
12. Darowski D, Jost C, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A,
Brünker P, Mössner E, Umaña P, Kobold S, Klein C.
P329G-CAR-J: A novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation
Protein Engineering, Design & Selection (PEDS), 2019, (eJournal)
JIF 2.0
11. Bellmann L, Cappellano G, Schachtl-Riess J.F., Prokopi A, Seretis A, Ortner D, Tripp CH,
Brinckerhoff CE, Mullins DW, Stoitzner P.
A TLR7 agonist shapes the effector immune cells during BRAF-targeted therapy in a preclinical
melanoma model.
International Journal of Cancer 2020; 46:1409-1420
JIF 5.0
10. Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz
Simoes AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ,
Met O, Becker JC, Donia M, Desler C and thor Straten P.
MERTK acts as a costimulatory receptor on human CD8+ T cells
American Association for Cancer Research 2019; 7:1472-1484
JIF 10.2
9. Karches CH, Benmebarek MR, Schmidbauer ML, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha BL, Lesch S, Heise C, Murr R, vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein C and Kobold S.
Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy
Clinical Cancer Research 2019; (accepted)
JIF 10.2
8. Liu X, Li J, Cadilha B, Markota A, Voigt C, Huang Z, Lin P, Wang D, Juncheng D, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel Ch, Uhl B, Briukhovetska D, Suarez Gosalvez J, Kobold S, Gires O, Wang H.
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Science Advances 2019; in press.
JIF 11.5
7. Heise T, Pijnenborg JFA, Büll C, van Hilten N, Kers-Rebel ED, Balneger N, Elferink H, Adema GJ, Boltje TJ.
Potent Metabolic Sialylation Inhibitors Based on C-5-Modified Fluorinated Sialic Acids.
J Med Chem 2019 Jan 24;62(2):1014-1021
JIF 6.3
2018
6. Büll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, Bloemendal VR, Boon L, van der Vlag J, Heise T, den Brok MH, Adema GJ.
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
Cancer Res 2018; 78(13):3574-3588
JIF 9.1
5. Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, Pockley AG, Ball GR, Powe DG, Regad T.
MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.
Cell Death Dis 2018; 9(3):344.
JIF 4.6
4. Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha B, Duewell P, Endres S, Kobold S.
PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma.
Frontiers in Immunology 2018; 9:1955.
JIF 5.5
3. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Science 2018; 359(6371):91-97.
JIF 41.0
2017
2. Olmeda D, Cerezo-Wallis D; Riveiro-Falkenbach E; Pennacchi PC; Contreras-Alcalde M, Ibarz N, Cifdaloz M, Catena X, Calvo TG, Cañón E, Alonso-Curbelo D, Suarez J, Osterloh L, Graña O, Mulero F, Megías D, Cañamero M, Martínez-Torrecuadrada JL, Mondal C, Di Martino J, Lora D, Martinez-Corral I, Bravo-Cordero JJ, Muñoz J, Puig S, Ortiz-Romero P, Rodriguez-Peralto JL, Ortega S, Soengas MS.
Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine.
Nature 2017; 546(7660):676-680.
JIF 44.9
1. Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt K, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler W, Schnurr M, Rothenfußer S, Endres S, Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.
Proceedings of the National Academy of Sciences 2017; 10:1073.
JIF 9.6
Reviews
2019
4. Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S.
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
Cells 2019 May 17;8(5)
JIF 4.8
3. Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S.
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.
Int J Mol Sci. 2019 Mar 14;20(6).
JIF 3.9
2018
2. Gottschlich A, Endres S, Kobold S.
Can we use interleukin-1β blockade for lung cancer treatment?
Transl Lung Cancer Res 2018;7(Suppl 2):S160-S164.
JIF 1.8
1. Kobold S, Pantelyushin S, Rataj F, vom Berg J.
Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy.
Frontiers in Oncology 2018; 8:285.
JIF 4.4
